ReviewHuman vaccines & immunotherapeutics2026
Elranatamab: A novel B-cell maturation T-cell engager.
Review in Human vaccines & immunotherapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
B-cell maturation antigen (BCMA) is a highly expressed transmembrane receptor on malignant plasma cells, mediating cell survival. These characteristics make it an attractive target for novel cellular and immunotherapies. Elranatamab is a bispecific antibody targeting BCMA on plasma cells and CD3 on T cells. This leads to immune cell activation and the release of granzymes and perforins, with attendant killing of target cells. Overactivation of the immune system can lead to cytokine release syndrome (CRS) and immune cell associated neurotoxicity syndrome (ICANS). Compared to similar agents, elranatamab has a favorable safety profile with robust efficacy. It is currently approved for relapsed/refractory multiple myeloma with clinical trials evaluating its use in combination and in earlier lines of therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.